KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Receivables - Net (2016 - 2024)

Historic Receivables - Net for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q4 2024 value amounting to $25.0 million.

  • CRISPR Therapeutics AG's Receivables - Net fell 8750.0% to $25.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $25.0 million, marking a year-over-year decrease of 8750.0%. This contributed to the annual value of $25.0 million for FY2024, which is 8750.0% down from last year.
  • As of Q4 2024, CRISPR Therapeutics AG's Receivables - Net stood at $25.0 million, which was down 8750.0% from $200.0 million recorded in Q4 2023.
  • CRISPR Therapeutics AG's Receivables - Net's 5-year high stood at $200.0 million during Q4 2023, with a 5-year trough of $33000.0 in Q2 2020.
  • In the last 5 years, CRISPR Therapeutics AG's Receivables - Net had a median value of $150000.0 in 2021 and averaged $23.0 million.
  • In the last 5 years, CRISPR Therapeutics AG's Receivables - Net plummeted by 9940.28% in 2021 and then skyrocketed by 10596060.61% in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Receivables - Net (Quarter) stood at $144000.0 in 2020, then soared by 111.81% to $305000.0 in 2021, then plummeted by 83.93% to $49000.0 in 2022, then soared by 408063.27% to $200.0 million in 2023, then tumbled by 87.5% to $25.0 million in 2024.
  • Its Receivables - Net stands at $25.0 million for Q4 2024, versus $200.0 million for Q4 2023 and $70.0 million for Q2 2023.